CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...

Researchers compared the efficacy of various treatment modalities for cutaneous squamous cell carcinoma in situ.

In addition, the Company’s research and preclinical development candidates include CTX340 and CTX450, targeting angiotensinogen (AGT) for refractory hypertension and 5’-aminolevulinate ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...